Evidence map›Paper›PMID 34046709›Full record

ReviewPediatric radiology2022

How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.

Heike E Daldrup-Link, Ashok J Theruvath, Ali Rashidi, Michael Iv, Robbie G Majzner, Sheri L Spunt, Stuart Goodman, Michael Moseley

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Heike E Daldrup-LinkDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Lucile Packard Children's Hospital, Stanford University, 725 Welch Road, Stanford, CA, 94305-5614, USA. H.E.Daldrup-Link@stanford.edu.ORCID http://orcid.org/0000-0002-4929-819X
Ashok J TheruvathDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Lucile Packard Children's Hospital, Stanford University, 725 Welch Road, Stanford, CA, 94305-5614, USA.
Ali RashidiDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Lucile Packard Children's Hospital, Stanford University, 725 Welch Road, Stanford, CA, 94305-5614, USA.
Michael IvDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Lucile Packard Children's Hospital, Stanford University, 725 Welch Road, Stanford, CA, 94305-5614, USA.
Robbie G MajznerDivision of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, CA, USA.
Sheri L SpuntDivision of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, CA, USA.
Stuart GoodmanDepartment of Orthopedic Surgery, Stanford University, Stanford, CA, USA.
Michael MoseleyDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Lucile Packard Children's Hospital, Stanford University, 725 Welch Road, Stanford, CA, 94305-5614, USA.
Lucile Packard Children's Hospital · USStanford University · US

Funding

Monitoring of Stem Cell Engraftment in Arthritic Joints with MR ImagingR01AR054458 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DALDRUP-LINK, HEIKE ELIZABETH · 2008 to 2021
$6.7M
Personalized Whole Body Staging for Children with Cancer: A Solution to the Conundrum of Long-Term Side Effects from CT and PET/CT ScansR01HD081123 · NICHD · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH · 2015 to 2019
$2.5M
Eunice Kennedy Shriver National Institute of Child Health and Human Development R01 HD081123ANIAMS NIH HHS R01 AR054458NIAMS NIH HHS R01AR054458NICHD NIH HHS R01 HD081123
6 · The paper itself

Abstract

Gadolinium chelates have been used as standard contrast agents for clinical MRI for several decades. However, several investigators recently reported that rare Earth metals such as gadolinium are deposited in the brain for months or years. This is particularly concerning for children, whose developing brain is more vulnerable to exogenous toxins compared to adults. Therefore, a search is under way for alternative MR imaging biomarkers. The United States Food and Drug Administration (FDA)-approved iron supplement ferumoxytol can solve this unmet clinical need: ferumoxytol consists of iron oxide nanoparticles that can be detected with MRI and provide significant T1- and T2-signal enhancement of vessels and soft tissues. Several investigators including our research group have started to use ferumoxytol off-label as a new contrast agent for MRI. This article reviews the existing literature on the biodistribution of ferumoxytol in children and compares the diagnostic accuracy of ferumoxytol- and gadolinium-chelate-enhanced MRI. Iron oxide nanoparticles represent a promising new class of contrast agents for pediatric MRI that can be metabolized and are not deposited in the brain.

Indexed as

Ferrosoferric OxideGadoliniumAdultChildContrast MediaHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyTissue DistributionContrast MediaFerrosoferric OxideGadoliniumChildrenContrast agentFerumoxytol iron oxide nanoparticlesMagnetic resonance imaging

Identifiers

PMID34046709
PMCPMC8626538
OpenAlexW3165736379

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.